Lau, WCY; Cheung, C-L; Man, K; Chan, EW; Sing, CW; Lip, GYH; Siu, CW; ... Wong, I; + view all Lau, WCY; Cheung, C-L; Man, K; Chan, EW; Sing, CW; Lip, GYH; Siu, CW; Lam, KY; Lee, ACH; Wong, I; - view fewer (2020) Association between treatment with apixaban, dabigatran, rivaroxaban, or warfarin and the risk of osteoporotic fractures among patients with atrial fibrillation: A population-based cohort study. Annals of Internal Medicine , 173 (1) pp. 1-9. 10.7326/M19-3671.

Preview

Text M19-3671-manuscript.pdf - Accepted Version Download (1MB) | Preview

Abstract

Background: It is unclear whether anticoagulant type is associated with the risk for osteoporotic fracture, a deleterious complication of anticoagulants among patients with atrial fibrillation (AF). Objective: To compare the risk for osteoporotic fracture between anticoagulants. Design: Population-based cohort study. Setting: Territory-wide electronic health record database of the Hong Kong Hospital Authority. Participants: Patients newly diagnosed with AF between 2010 and 2017 who received a new prescription for warfarin or a direct oral anticoagulant (DOAC) (apixaban, dabigatran, or rivaroxaban). Follow-up ended on 31 December 2018. Measurements: Osteoporotic hip and vertebral fractures in anticoagulant users were compared using propensity score–weighted cumulative incidence differences (CIDs). Results: There were 23 515 patients identified (3241 apixaban users, 6867 dabigatran users, 3866 rivaroxaban users, and 9541 warfarin users). Overall mean age was 74.4 years (SD, 10.8), ranging from 73.1 years (warfarin) to 77.9 years (apixaban). Over a median follow-up of 423 days, 401 fractures were identified (crude event number [weighted rate per 100 patient-years]: apixaban, 53 [0.82]; dabigatran, 95 [0.76]; rivaroxaban, 57 [0.67]; and warfarin, 196 [1.11]). After 24-month follow-up, DOAC use was associated with a lower risk for fracture than warfarin use (apixaban CID, −0.88% [95% CI, −1.66% to −0.21%]; dabigatran CID, −0.81% [CI, −1.34% to −0.23%]; and rivaroxaban CID, −1.13% [CI, −1.67% to −0.53%]). No differences were seen in all head-to-head comparisons between DOACs at 24 months (apixaban vs. dabigatran CID, −0.06% [CI, −0.69% to 0.49%]; rivaroxaban vs. dabigatran CID, −0.32% [CI, −0.84% to 0.18%]; and rivaroxaban vs. apixaban CID, −0.25% [CI, −0.86% to 0.40%]). Limitation: Residual confounding is possible. Conclusion: Among patients with AF, DOAC use may result in a lower risk for osteoporotic fracture compared with warfarin use. Fracture risk does not seem to be altered by the choice of DOAC. These findings may help inform the benefit–risk assessment when choosing between anticoagulants. Primary Funding Source: The University of Hong Kong and University College London Strategic Partnership Fund.

Downloads since deposit

Loading...

192Downloads

Download activity - last month

Export as XMLJSONCSV

Loading...

Download activity - last 12 months

Export as XMLCSVJSON

Loading...

Downloads by country - last 12 months

Export as CSVJSONXML

1.	United States	9
2.	Hong Kong	4
3.	United Kingdom	4
4.	Taiwan	3
5.	Russian Federation	3
6.	Indonesia	2
7.	Australia	2
8.	China	2
9.	Norway	1
10.	Canada	1

102550all

Archive Staff Only

View Item